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Summary Murine fibrosarcoma cells (SSK) exhibit a transient cisplatin resistance after low-dose irradiation
(5 x 2 Gy) in vitro and in vivo. When resistance is lost, it can be restored by a single drug exposure which,
without preirradiation, does not generate cisplatin resistance in parental cells. There is no cross-resistance to
radiation. Metallothioneins. which are associated with cisplatin resistance after high-dose irradiation
(15 x 6 Gy). do not correlate with induction and loss of cisplatin resistance after low-dose irradiation. Since
cisplatin survival curves are also monotonous when drug resistance diminishes, an adaptive response is more
likely than a mutational event to underlie cisplatin-induced resistance. Drug resistance can be overcome by
combined exposure to cisplatin in the presence of the phosphodiesterase inhibitor 3-isobutyl-l-methylxanthine
(IBMX). Under these conditions. cisplatin sensitivity is increased 2.4- to 2.8-fold in the resistant strains
compared with only 1.5- to 1-8-fold in the parental cells. The cellular platinum content with and without
IBMX treatment is not significantly different in sensitive and resistant cells. Loss of drug resistance correlates
with a decrease in cisplatin sensitisation by IBMX. This suggests that cisplatin resistance after low-dose
irradiation may be associated with alterations of the cAMP-dependent signal transduction pathway.
Combined modality therapy involving ionising radiation and
cisplatin has widely been used in various treatment protocols;
however, the acquisition of drug resistance limits its
effectiveness. There is evidence that resistance is induced not
only by the drug itself but also by irradiation (Osmak &
Perovic, 1989; Hill et al.. 1990; Dempke et al., 1992). Cis-
platin resistance generally develops more slowly and to much
lower levels than, for example, resistance to anthracyclines,
Typically. cisplatin-resistant cells are generated in vitro by
exposure to increasing concentrations of cisplatin over
months (Saburi et al., 1989; Twentyman et al., 1991; Kelland
et al., 1992; Christen et al., 1993) or to high radiation doses
(Eichholtz-Wirth et al., 1993a). A variety of molecular
mechanisms have been associated with cisplatin resistance,
including increased DNA repair (Hill et al., 1990; Dempke et
al., 1992; Zhen et al., 1992), enhanced drug detoxification by
protein or non-protein thiols (Saburi et al., 1989; Eichholtz-
Wirth et al., 1993a) and reduced drug accumulation (Kelland
et al., 1992; Christen et al., 1993).
We have previously described the induction of cisplatin-
resistant clones of murine fibrosarcoma cells in vitro by low-
dose cisplatin exposure (3-4 cycles; Eichholtz-Wirth et al.,
1993b), or by fractionated irradiation (Eichholtz-Wirth et al.,
1993a). In both cases, resistance was closely correlated with
elevated metallothioneins. As the radiation dose used was
rather high (15 x 6 Gy), the present experiments were
designed to answer the following questions:
1. Is cisplatin resistance also induced by lower radiation
dose and lower dose per fraction?
2. What is the time course and extent of cisplatin resist-
ance.
3. Is the mechanism responsible for cisplatin resistance the
same after low- and high-dose irradiation?
4. Can cisplatin resistance also be induced by irradiating
SSK tumours in vivo?
Materials and methods
Cell lines and induction ofresistance
Monolayers Mouse fibrosarcoma cells (SSK) were grown as
monolayer cultures in Eagle's minimal essential medium
Correspondence: H. Eichholtz-Wirth
Present address: Strahlenbiologisches Institut der Universitat.
Schillerstrasse 47, D80336 Munich, Germany.
Received 7 February 1994; and in revised form 20 May 1994.
(MEM) supplemented with 10% newborn calf serum, 0.01%
neomycin and 0.035% sodium bicarbonate in a humidified
carbon dioxide incubator at pH 7.4 and 37C.
Approximately IO5 SSK cells were irradiated in vitro with
5 x 2 Gy over 7 days, using a gamma cell 40 caesium-137
source (AECL Industria, Canada) at a dose rate of
1.2 Gy min-'. During each of the subsequent subcultures of
the preirradiated cells (after about 5-6 cell divisions) survival
to cisplatin was measured by a clonogenic assay using
0.2 jLgml-1 cisplatin under permanent exposure (cisplatin
solution, Behring, Marburg, Germany). After loss of drug
resistance (passage 4-6), 5 x 105 cells were submitted once to
a conditioning cisplatin treatment (0.5 ILg ml-', 48 h). At
each of the following subcultures, cells were again tested for
sensitivity to cisplatin as described above (0.2f.gml-': per-
manent exposure).
Tumour SSK cells, which grow in vitro and in vivo, were
transplanted subcutaneously into syngeneic C3H mice. At a
tumour size of 100 ± 20 mg, the tumour was irradiated
(5 x 7 Gy over 7 days under conditions of local hypoxia.
roughly equivalent to 5 x 2 Gy in vitro). Subsequently, the
tumour was removed and a single-cell suspension prepared.
The cells were then grown in vitro and tested as described
above. Cisplatin conditioning was carried out either in vivo
following irradiation by a single i.p. injection of 10 mg kg-',
24 h before sacrifice or in vitro when drug resistance was lost.
All subsequent procedures were as described above for the in
vitro culture.
Measurement ofdrug and radiation sensitivity
To establish cisplatin survival curves, exponentially growing
cells were appropriately diluted and the drug added to the
culture medium for permanent exposure.
To generate radiation survival curves, cells were appropri-
ately diluted, allowed to attach to the glass surface for 4 h
and then exposed to graded single doses of y-rays from a
gamma cell 40 caesium-137 source at a dose rate of
1.2 Gy min '.
For cytotoxicity studies, cells were exposed to graded con-
centrations of the following agents, diluted in Hanks' solu-
tion and exposed under permanent treatment: cadmium
chloride (Sigma Chemicals); adriamycin (Farmitalia); vincris-
tine (Lilly).
Cells were exposed to nifedipine (5pgmm1'; Ratiopharm
Blaubeuren, Germany) in the presence of graded concentra-
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tions of cisplatin; after 24 h the cells were rinsed twice with
Hanks' solution and new medium was added.
IBMX (Sigma) was dissolved in ethanol and freshly diluted
in Hanks' solution; 0.5 mM IBMX was used in all experi-
ments. ExponentiaUy growing ceUls were allowed to attach to
the glass surface overnight. The cells were exposed to IBMX
in the presence of graded concentrations of cisplatin for 1 h;
the cells were then rinsed twice with Hanks' solution and new
medium was added. The surviving fractions (SFs) were cor-
rected for the toxicity of IBMX alone, which amounted to
SF = 0.8-0.95. The final concentration of the solvent ethanol
was <0.05% in the growth medium, which had no inhibitory
effect on the cell growth. Enhancement factors were cal-
culated from the IC,o values of the survival curves of cis-
platin alone versus cisplatin in the presence of IBMX.
Following any of the indicated treatments, cells were
incubated for 7-9 days. The colonies were then stained with
methylene blue and those containing more than 50 cells were
counted. The surviving fraction (SF) was calculated from the
ratio of mean colony yield of treated to untreated cells.
In Figures 1-4, single experiments are presented, using
three flasks per data point. For complete survival curves
experiments were repeated at least three times and the
mean ± s.d. is given. The IC,O (drug concentration necessary
to reduce cell survival to 10%) was determined from the
survival curves and the resistance factor calculated (RF = ICI0
resistant cells/IC10 sensitive cells).
GSH andprotein determination
Cells in the exponential growth phase were used for GSH
determination according to Tietze (1969). Protein was
assayed according to the procedure of Lowry et al. (1951),
with bovine serum albumin as standard.
The resistant cells tested for cadmium chloride and GSH
(Table II) were irradiated either in vitro (experiments 3 and 4)
or in vivo (experiments 2, 5, 6 and 7); experiments 2, 3 and 4
were cisplatin conditioned.
Cellular platinum concentration
The cellular platinum content was determined by proton-
induced characteristic X-ray emission (PIXE), as described in
detail by Eichholz-Wirth & Hietel (1990). Approximately 106
cells were exposed to 40 Lg ml ' cisplatin for 1 h in the
absence or presence of IBMX and the platinum content was
measured in duplicate samples and repeated once.
Results
After a radiation dose of 5 x 2 Gy delivered in vitro over 7
days, uncloned SSK cells exhibit a transient cisplatin resist-
ance which lasts for about 15-25 cell cycles (3-5 passages),
whereafter the sensitivity of the untreated control cells is
resumed (Figure 1). If these preirradiated cells are submitted
to a single cisplatin conditioning (0.5 Lg ml-, 48 h), drug
resistance is restored and is maintained over at least six and
presumably more than 10 passages (Figure 2). The same drug
exposure alone without preirradiation does not generate cis-
platin resistance.
A similar cisplatin resistance is also observed when solid
subcutaneous SSK tumours are submitted to low-dose local
irradiation (5 x 7 Gy under hypoxia, equivalent to 5 x 2 Gy
in vitro, Figure 3) given either alone or in combination with
subsequent cisplatin conditioning treatment in vitro or in vivo
(Figure 4).
Cell survival as a function of increasing cisplatin concen-
tration is presented in Figure 5 for the sensitive parental SSK
cells and some preirradiated strains with or without subse-
quent cisplatin conditioning. When cisplatin resistance
diminishes, the slope of the survival curve increases and
eventually matches that of the unirradiated control cells.
Drug resistance, calculated from the ratio of the IC,O drug
concentrations of resistant over parent SSK cells, amounts to
RF= 1.9-2.1.
The growth characteristics of sensitive and resistant cells
are similar except that the doubling times are slightly longer
in the resistant cells (12-15 h compared with 11-13 h in the
parental cells). The cell morphology is unchanged; the pro-
tein content of the cells is not significantly different and
ranges from 0.33 to 0.41 mg 106 cells. The cellular platinum
content amounts to 1.6-1.8 ng 10-6 cells for both cells at a
cisplatin exposure dose of 20 Lgml-' for 1 h. There is no
cross-resistance to doxorubicin or vincristine (Table I).
Exposing the cells to the calcium antagonist nifedipine
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Fge 1 Surviving fraction of SSK cells in vitro to cisplatin as a
function of the time course after irradiation. The cells were
irradiated (5 x 2 Gy over 7 days) and their cisplatin sensitivity
tested in the subsequent passages by continuous drug exposure
(0.2Mg ml-' cisplatin); results of three single experiments. Shaded
area: cisplatin sensitivity of unirradiated control cells (mean of
three parallel experiments).
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Fgue 2 Cisplatin sensitivity of SSK cells preirradiated and
exposed to conditioning cisplatin treatment (0.5pLgml-l for 48 h;
closed symbols) or given conditioning cisplatin treatment alone
(open symbols). Cisplatin sensitivity was then tested in the subse-
quent passages by continuous drug exposure (0.21pgml1' cis-
platin) as described in Figure 1. Shaded area: cisplatin sensitivity
of control cells (mean of four parallel experiments).
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(5 gLg ml-') in the presence of graded doses of cisplatin for
24 h reduces the surviving fraction of both sensitive and
resistant cells by almost the same extent (about 2.5-fold,
Table II).
GSH levels and especially cadmium chloride toxicity, an
indirect measure of metallothioneins (Hamer. 1986), vary
considerably among the resistant strains (Table II). These
were tested in an early passage. when the cells exhibited
cisplatin resistance (R). or later, when they had lost their
drug resistance (S). Cadmium chloride toxicity ranges from
no change compared with the parental cells (experiments 3, 4
and 7) to reduced toxicity (experiments 2, 5 and 6). and
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Figure 3 Cisplatin sensitivity of SSK cells, previously unir-
radiated (V, 0) or irradiated (V, *) in vivo (subcutaneous
tumour) by 5 x 7 Gy over 7 days under local hypoxia (clamp);
the cells were subsequently plated in vitro and tested for cisplatin
sensitivity during the following passages by continuous drug
exposure (0.2 gig ml-' cisplatin) as described in Figure 1. Results
of two single experiments of each modality. Surviving fraction to
continuous cisplatin treatment of the unirradiated control cells
was <0.03.
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Figue 4 Cisplatin sensitivity of SSK cells preirradiated in vivo
as described in Figure 3. Additional cisplatin conditioning
(0.5igml-' for 48h) was carried out either in vivo (0) or in
vitro (V, *). (0) Cisplatin conditioning in vivo without preir-
radiation. Cisplatin sensitivity was tested in the subsequent pas-
sages by continuous drug exposure (0.2 jug ml- cisplatin) as des-
cribed for the in vitro data (Figure 2). Results of single
experiments. Surviving fraction to continuous cisplatin treatment
of the control cells was <0.03.
Table I Cytotoxicity data of SSK cells and resistant SSK sublines
Cisplatin ±
Cell line Doxorubicina Vincristine' Cisplatin'4 nifedipine'4
SSK cells' 0.32 0.04 0.18 0.04 0.18 ± 0.015 0.072 ± 0.004
Resistant 0.35 ± 0.05* 0.22 ± 0.06* 0.38 ± 0.02 0.165 ± 0.008
sublinesd
'ICIo values (jug ml-'), derived from survival curves after permanent drug exposure. bIC10 values (igml-'), derived from survival curves after a 24 h drug exposure;
cisplatin treatment alone (bl) or cisplatin exposure in the presence of nifedipine
(5 ILg ml', b2). cMean of at least three different experiments (± s.d.). dMean of 2-4
different sublines with and without cisplatin conditioning (± s.d.). *Not significant
compared with the parental SSK cells.
Table II Comparison of cadmium chloride toxicity and GSH levels in the
sensitive parental cells and some resistant SSK strains
Cadniwn chloride" GSHA
Cell line R S R S
Parental SSK cells 17.5 ± 2.6 2.7 ± 0.24
Resistant SSK
experimentsc
2 30.5** 17.6 ± 0.8* 4.8** 2.7*
3 18.4* 17.3* 2.6*
4 19.9* 18.6 1.8**
5 32.2* 28.7** 2.8** 2.6*
6 31.0** 27.4 ± 3.2** 3.0* 3.04*
7 19.5* 3.3
'Cadmium chloride concentration necessary to reduce cell survival to 10%
after permanent cadmium chloride exposure; data are derived from the survival
curves and are expressed in lim. 'Total GSH (ng mg protein-'); means ± s.d.
from three separate experiments or single data. cSome resistant strains were
tested before (R) and after they had lost cisplatin resistance (S). *Not
significantly different from parental SSK cells. **P<0.01 as compared with
the parental SSK cells.
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Cisplatin concentration (jig ml-')
Fgre 5 Cell survival as a function of cisplatin concentration
(continuous exposure). Parental SSK cells (0, mean ± s.d. of
three separate experiments); preirradiated cells (0); preirradiated
cells plus drug conditioning (0.5 iLg ml-' for 48 h), tested two (V)
or six (V) passages later (single experiments).
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F re 6 Radiation sensitivity of SSK control cells (0) or pre-
irradiated cells (0) and preirradiated cells with cisplatin condi-
tioning (0.5 ;tg ml-' for 48 h, V). Mean of at least three experi-
ments ± s.d.
either increases upon loss of cisplatin resistance (experiment
2) or remains low (experiments 5 and 6).
Parental and resistant strains, tested before and after cis-
platin conditioning. are almost equally radiosensitive (Figure
6).
If parental and resistant cells are exposed to graded con-
centrations of cisplatin for 1 h in the presence of the phos-
phodiesterase inhibitor IBMX, the drug sensitivity is
enhanced (Figure 7). At the concentration used, IBMX alone
reduces cell survival by 0.05-0.2. The combined exposure of
IBMX and cisplatin results in a 2.4- to 2.8-fold increase in
drug toxicity in the resistant cells compared with only 1.5- to
1.8-fold in the parental SSK cells (IC,O values). Loss of drug
resistance coincides with a decrease in drug sensitisation by
IBMX; the survival curves gradually approximate those of
the parental cells and the increase in drug sensitivity by
Cisplatin concentration (jg ml-')
Figre 7 Cell survival as a function of cisplatin concentration in
the presence or absence of 0.5 mM IBMX for 1 h; open symbols:
cisplatin exposure alone; closed symbols: cisplatin plus IBMX;
parental SSK cells (0, 0); preirradiated SSK cells (V, V).
Mean of at least three experiments ± s.d.
IBMX is reduced to 1.6-1.9. There is a slight increase in
cellular platinum content of 8-18% after IBMX treatment in
both sensitive and resistant cells, but this is not significantly
different between sensitive and resistant cells.
Disczes
In the present study it is demonstrated that low-dose irradia-
tion is sufficient to generate cisplatin resistance in murine
fibrosarcoma cells. Induction of cisplatin resistance therefore
does not require artificially high or escalating doses applied
over months as described in the literature, but apparently can
arise after clinically relevant radiation doses.
In SSK cells, resistance is conferred not only in vitro but
also following irradiation of the tumour in vivo. The method
of cisplatin induction does not affect the cellular cisplatin
resistance measured in vitro. Resistance is independent of
interactions between the tumour and the normal tissue, in
contrast to a report by Teicher et al. (1990), in which cis-
platin resistance in the EMT6 tumour only developed in vivo
and was not observed in vitro.
While the cisplatin resistance in SSK cells is only transient
and the level of resistance is low, it would be sufficient to
reduce the efficacy of concomitant chemotherapy and also to
interfere with later sequential combined-modality therapy
regimens. This is demonstrated by a single cisplatin condi-
tioning treatment, given at a time when the sensitivity of
drug-resistant cells has already returned to that of unir-
radiated control cells. In fact, cisplatin resistance was not
only restored but even more pronounced than initially found
after irradiation. In comparison with the drug resistance seen
in previous studies using high-dose irradiation (Eichholtz-
Wirth et al., 1993a), resistance is lower in the present
experiments (RF 2 vs 5) and it remains stable for a shorter
period only (25-40 vs 60-150 cell cycles), indicating
differences in the underlying mechanisms.
There is evidence that multiple mechanisms are involved in
the aquisition of cisplatin resistance in all cell lines (Dempke
et al., 1992; Brown et al., 1993; Eichholtz-Wirth et al., 1993a;
Mellish et al., 1993). Metallothioneins were recently described
to be the main reason for cisplatin resistance in SSK cells
following low-dose drug exposure (Eichholtz-Wirth et al.,
1993b) as well as following high-dose irradiation (Eichholtz-
Wirth et al., 1993a). In the present experiments, both protein
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and non-protein thiols were elevated only in some resistant
cells, but their levels varied considerably and did not neces-
sarily correlate with loss of cisplatin resistance. The survival
curves to cisplatin as a function of drug concentration give
some indication on the changes involved in cisplatin resis-
tance and loss of drug resistance: the survival curves are
monotonous even when drug resistance diminishes without
any biphasic curve shape, as would be expected in a resistant
subpopulation. For the uncloned population under study this
would suggest adaption rather than a mutational event.
Cisplatin resistance does not confer cross-resistance to
irradiation in these preirradiated SSK cells; neither the slopes
of the survival curves nor the shoulders differ significantly
from those of the parental cells. Induction of cisplatin resist-
ance without alteration of the radiation response has been
reported in oncogene-activated cells. Transformation of a
human epithelial cell line by the ras oncogene does not
modify the response to irradiation but correlates with cis-
platin resistance; recognition and/or excision of cis-
platin-DNA adducts appears to be involved (Alapetite et al.,
1993). Sklar and Prochownik (1991) showed a modulation of
cisplatin sensitivity without alteration of the radiation re-
sponse in correlation with c-myc expression in F-MEL cells.
These authors concluded that c-myc may directly or
indirectly regulate a process of DNA repair that specifically
affects the type of DNA cross-linking damage caused by
cisplatin but not by irradiation. Cell cycle-sensitive processes
do not appear to be involved.
Drug resistance can be overcome by exposing the cells to
cisplatin in the presence of the phosphodiesterase inhibitor
IBMX. This xanthine derivative inhibits the degradation of
the short-lived cAMP and may affect the cAMP-dependent
protein kinase signalling pathway. Modulation of protein
kinases and the second messenger cAMP have been reported
to interfere with cisplatin cytotoxicity, and elevated levels of
kinases as well as cAMP have been detected in drug-resistant
cells (Grunicke et al., 1989; Mann et al., 1991). IBMX sensi-
tises the resistant SSK cells more effectively to the cytotoxic
action of cisplatin than the parental SSK cells, and this is
negatively correlated with the loss of drug resistance: a
decrease in drug resistance is accompanied by reduced IBMX
sensitisation. This cisplatin sensitisation by IBMX is not
associated with a considerable increase in cellular platinum
accumulation as described by Mann et al. (1991) and
Christen et al. (1993) in human ovarian carcinoma cells.
However, contrary to our results, their resistant sublines are
characterised by a reduced IBMX effect on cisplatin toxicity
together with decreased expression of P-tubulin, the tubulin-
associated p53 protein and also reduced cAMP-dependent
phosphorylation (Christen et al.. 1993). In SSK cells. neither
vincristine nor the calcium antagonist nifedipine - both
agents are associated with membrane effects - exhibited a
differential effect on parental and resistant SSK cells.
This suggests that drug accumulation does not play an
essential role in the acquisition of cisplatin resistance in SSK
cells, as was later confirmed by the IBMX data. Inhibition of
protein kinase C by staurosporin, which may also interfere
with growth-related membrane functions and help to over-
come cisplatin resistance, as suggested by Grunicke et al.
(1989), is not effective in resistant SSK cells (data not
shown). Since most cAMP-dependent events are mediated by
the cAMP-dependent protein kinase, with the exception of
the direct activation of ion channels by cAMP (Otten et al.,
1991), the cAMP-dependent protein kinase signalling path-
way may be involved in the aquisition of cisplatin resistance
in SSK cells.
Phosphodiesterase inhibitors have also been demonstrated
to inhibit p53 protein (Kastan et al., 1991), which is rapidly
increased upon DNA damage following irradiation or cis-
platin treatment as part of a signal transduction pathway
(Kastan et al., 1991; Tishler et al., 1993). Increased p53
protein levels have been reported in cisplatin-resistant
ovarian carcinoma cells compared with the parental cells
(Brown et al., 1993).
Further studies on the mechanisms of cisplatin resistance
in SSK cells will now be carried out to obtain more inform-
ation on the regulation of radiation-induced cisplatin resist-
ance.
In summary our experiments demonstrate that low-dose
irradiation induces transient cisplatin resistance in SSK cells
in vitro and in vivo. The level of resistance is low and the
mechanisms are different from those previously described
after high-dose irradiation (Eichholtz-Wirth et al.. 1993a), in
which resistance correlated with the elevation of metallothi-
oneins. In the resistant SSK cells. described above. cisplatin
sensitivity can be restored by drug exposure in the presence
of the phosphodiesterase inhibitor IBMX, suggesting that
alterations of the cAMP-dependent transduction pathway
may be involved in cisplatin resistance after low-dose irradia-
tion.
We would like to thank Miss Renate Hintermaler for her skilful
technical assistance.
AbbreviatouB cisplatin, cis-diamminedichloroplatinum (II); GSH.
glutathione; IBMX, 3-isobutyl-l-methylxanthine; SF. surviving frac-
tion; RF. resistance factor.
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